Hagens Berman Sobol Shapiro LLP said a securities class action has been filed involving PROCEPT BioRobotics Corporation (NASDAQ: PRCT), alleging the company misled investors about U.S. sales of single-use handpieces used in its Aquablation therapy for enlarged prostate patients. The proposed class covers investors who purchased or otherwise acquired PROCEPT common stock from February 28, 2024, through February 25, 2026, with a lead plaintiff deadline of September 22, 2026. The complaint alleges PROCEPT used repeated, late-quarter bulk discounts to encourage customers to place orders exceeding procedure demand, pulling sales forward and inflating reported handpiece unit sales and revenue. Investors received partial disclosures through August 6, November 4 and February 25 results, including a cumulative excess inventory of more than 10,000 handpieces, a 30% sequential decline in U.S. handpiece sales and the elimination of the previously undisclosed discount program. The release said PROCEPT shares had declined $22.06, or more than 48%, from the August 6, 2025 close by February 25, 2026. Hagens Berman partner Reed Kathrein is leading the investigation, and the firm is also seeking information from potential whistleblowers eligible for SEC awards of up to 30% of a successful recovery.